

**Table 1: Minimum Frequency of Laboratory Monitoring During Year 1 of Antiretroviral Therapy or at Regimen Change (Rating: A3)**

| Laboratory Test      |                 | Entry to Care or ART Initiation | At 4 Weeks | At 3 Months | At 6 Months | At 12 Months |
|----------------------|-----------------|---------------------------------|------------|-------------|-------------|--------------|
| Hepatic panel [a]    |                 | X                               |            | X           |             | X            |
| Random blood glucose |                 | X                               |            | X           |             | X            |
| eGFR [b]             | With TDF        | X                               | X          | X           | X           | X            |
|                      | Without TDF [c] | X                               |            |             | X           | X            |
| Proteinuria [d]      | With TDF        | X                               |            | X           |             | X            |
|                      | Without TDF     | X                               |            |             |             | X            |
| Complete blood count | With ZDV        | X                               | X          | X           | X           | X            |
|                      | Without ZDV     | X                               |            |             |             |              |

**Abbreviations:** ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.

**Notes:**

- AST, ALT, alkaline phosphates, and total bilirubin.
- Patients with decreased eGFR at baseline or those taking concomitant nephrotoxic drugs may need more frequent monitoring of renal function.
- Including TAF-containing regimens. See the section on *Screening for Organ-Specific Adverse Events > Nephrotoxicity* for more information.
- Urinalysis or urine protein-to-creatinine ratio.

**Table 2: Minimum Frequency of Laboratory Monitoring After Year 1 of Antiretroviral Therapy (Rating: A3)**

| Laboratory Test      |                 | Every 6 Months   | Every 1 Year |
|----------------------|-----------------|--|--------------|
| Hepatic panel [a]    |                 |  | X            |
| Random blood glucose |                 | X  |              |
| eGFR                 | With TDF        | X  |              |
|                      | Without TDF [b] |  | X            |
| Proteinuria [c]      | With TDF        |  | X            |
| Complete blood count | With ZDV        | X  |              |
|                      | Without ZDV     | See the NYSDOH AI guideline <i>Primary Care Approach</i> |              |

**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.

**Notes:**

- AST, ALT, alkaline phosphates, and total bilirubin.
- See the section on *Screening for Organ-Specific Adverse Events > Nephrotoxicity* for more information.
- Urinalysis or urine protein-to-creatinine ratio.